<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37155736</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Cognitive-Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019: Results of a Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>687</StartPage><EndPage>695</EndPage><MedlinePgn>687-695</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad257</ELocationID><Abstract><AbstractText Label="BACKGROUND">Severe fatigue following coronavirus disease 2019 (COVID-19) is prevalent and debilitating. This study investigated the efficacy of cognitive-behavioral therapy (CBT) for severe fatigue following COVID-19.</AbstractText><AbstractText Label="METHODS">A multicenter, 2-arm randomized controlled trial was conducted in the Netherlands with patients being severely fatigued 3-12 months following COVID-19. Patients (N = 114) were randomly assigned (1:1) to CBT or care as usual (CAU). CBT, targeting perpetuating factors of fatigue, was provided for 17 weeks. The primary outcome was the overall mean difference between CBT and CAU on the fatigue severity subscale of the Checklist Individual Strength, directly post-CBT or CAU (T1), and after 6 months (T2). Secondary outcomes were differences in proportions of patients meeting criteria for severe and/or chronic fatigue, differences in physical and social functioning, somatic symptoms, and problems concentrating between CBT and CAU.</AbstractText><AbstractText Label="RESULTS">Patients were mainly nonhospitalized and self-referred. Patients who received CBT were significantly less severely fatigued across follow-up assessments than patients receiving CAU (-8.8 [95% confidence interval {CI}, -11.9 to -5.8]); P &lt; .001), representing a medium Cohen's d effect size (0.69). The between-group difference in fatigue severity was present at T1 (-9.3 [95% CI, -13.3 to -5.3]) and T2 (-8.4 [95% CI, -13.1 to -3.7]). All secondary outcomes favored CBT. Eight adverse events were recorded during CBT, and 20 during CAU. No serious adverse events were recorded.</AbstractText><AbstractText Label="CONCLUSIONS">Among patients, who were mainly nonhospitalized and self-referred, CBT was effective in reducing fatigue. The positive effect was sustained at 6-month follow-up.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION">Netherlands Trial Register NL8947.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuut</LastName><ForeName>Tanja A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0003-1081-7025</Identifier><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Csorba</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braamse</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldenkamp</LastName><ForeName>Arnoud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Lung Medicine, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appelman</LastName><ForeName>Brent</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Experimental and Molecular Medicine, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assmann-Schuilwerve</LastName><ForeName>Eleonoor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Jeroen Bosch Hospital, 5223 GZ Den Bosch, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geerlings</LastName><ForeName>Suzanne E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and immunity, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibney</LastName><ForeName>Katherine B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, 3000 Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, 3000 Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanaan</LastName><ForeName>Richard A A</ForeName><Initials>RAA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Austin Health, Heidelberg, 3084 Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mooij-Kalverda</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olde Hartman</LastName><ForeName>Tim C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Primary and Community Care, Radboud Institute for Health Sciences, 6500 HB Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pau&#xeb;lsen</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and immunity, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Public Health Service of Amsterdam, 1018 WT Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slieker</LastName><ForeName>Kitty</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Bernhoven Hospital, 5406 PT Uden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and immunity, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keijmel</LastName><ForeName>Stephan P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieuwkerk</LastName><ForeName>Pythia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Institute for Infection and immunity, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovers</LastName><ForeName>Chantal P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoop</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Psychology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Public Health, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>MMW Fortschr Med. 2024 Mar;166(4):32-34. doi: 10.1007/s15006-024-3697-6</RefSource><PMID Version="1">38453853</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cognitive-behavioral therapy</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. F. M. reports funding from the Nederlands Kenniscentrum Chronische Vermoeidheid (NKCV) Foundation. C. P. R. reports grants as a payment to institution by the present study, the European Union Horizon 2020 Research and Innovation Framework Programme, and the Michael J. Fox Foundation; and has served as a member of the committee &#x201c;Pandemic Preparedness Plan&#x201d; of the Royal Netherlands Academy of Arts and Sciences and a member of the committee &#x201c;Long-term effects of COVID-19&#x201d; of the Health Council of the Netherlands. K. B. G. reports salary support (investigator grant [MRF1193727] 2021&#x2013;2025) by the MRFF/NHMRC, Australia; grants from the Partnership Project (APP1196396 2020&#x2013;2023, APP152807) and an Early Career Fellowship (APP1120816) by the NHMRC; Faculty of Medicine, Dentistry and Health Sciences (MDHS) Research Grant Support Scheme 2020 by the University of Melbourne; a Research Establishment Fellowship 2020 by the Royal Australasian College of Physicians&#x2013;GlaxoSmithKline; Seed Funding 2019 by the Melbourne Children's Research Institute; royalties for textbook (Manual of Travel Medicine Edition 4) by Springer Nature Singapore; and being a member of the Australian Technical Advisory Group of Immunisation and an expert member (representing the Australasian Society of Infectious Diseases) of the Communicable Diseases Network Australia. R. A. A. K. reports grants or contracts from MRFF/NHMRC, Mindgardens Neuroscience Network, and Austin Medical Research Foundation; and has served as advisory board member of the Psychae Institute, director of the Functional Neurological Disorder Society, director of the International Neuropsychiatry Association, and member of the Biotoxin-Related Illness Advisory Committee, Australian Department of Health. H. K. was supported for this study by the Netherlands Organization for Health Research and Development (ZonMw: project number 10430012010025, research program COVID-19), with payments made to institution; and grants from ZonMw to conduct research into long COVID and post-Lyme symptoms, from the Dutch Cancer Society, Multiple Sclerose research, Pfizer, and NKCV Foundation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>15</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37155736</ArticleId><ArticleId IdType="pmc">PMC10495128</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad257</ArticleId><ArticleId IdType="pii">7157021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salamanna &#xa0;F, Veronesi &#xa0;F, Martini &#xa0;L, Landini &#xa0;MP, Fini &#xa0;M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med &#xa0;2021; 8:653516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban &#xa0;F, Ling &#xa0;S, Lui &#xa0;LMW, et al. &#xa0;Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun &#xa0;2022; 101:93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Han &#xa0;Q, Zheng &#xa0;B, Daines &#xa0;L, Sheikh &#xa0;A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens &#xa0;2022; 11:269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Verveen &#xa0;A, Wynberg &#xa0;E, van Willigen &#xa0;HDG, et al. &#xa0;Severe fatigue in the first year following SARS-CoV-2 infection: a prospective cohort study. Open Forum Infect Dis &#xa0;2022; 9:ofac127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995073</ArticleId><ArticleId IdType="pubmed">35415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang &#xa0;L, Li &#xa0;X, Gu &#xa0;X, et al. &#xa0;Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med &#xa0;2022; 10:863&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky &#xa0;H, Patcai &#xa0;J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol &#xa0;2011; 11:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam &#xa0;MHB, Wing &#xa0;YK, Yu &#xa0;MWM, et al. &#xa0;Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors long-term follow-up. Arch Intern Med &#xa0;2009; 169:2142&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId></ArticleIdList></Reference><Reference><Citation>Morroy &#xa0;G, Keijmel &#xa0;SP, Delsing &#xa0;CE, et al. &#xa0;Fatigue following acute Q-fever: a systematic literature review. PLoS One &#xa0;2016; 11:e0155884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880326</ArticleId><ArticleId IdType="pubmed">27223465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulme &#xa0;K, Hudson &#xa0;JL, Rojczyk &#xa0;P, Little &#xa0;P, Moss-Morris &#xa0;R. Biopsychosocial risk factors of persistent fatigue after acute infection: a systematic review to inform interventions. J Psychosom Res &#xa0;2017; 99:120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28712416</ArticleId></ArticleIdList></Reference><Reference><Citation>Keijmel &#xa0;SP, Delsing &#xa0;CE, Bleijenberg &#xa0;G, et al. &#xa0;Effectiveness of long-term doxycycline treatment and cognitive-behavioral therapy on fatigue severity in patients with Q fever fatigue syndrome (Qure Study): a randomized controlled trial. Clin Infect Dis &#xa0;2017; 64:998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">28329131</ArticleId></ArticleIdList></Reference><Reference><Citation>Menting &#xa0;J, Tack &#xa0;CJ, van Bon &#xa0;AC, et al. &#xa0;Web-based cognitive behavioural therapy blended with face-to-face sessions for chronic fatigue in type 1 diabetes: a multicentre randomised controlled trial. Lancet Diabetes Endocrinol &#xa0;2017; 5:448&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">28462869</ArticleId></ArticleIdList></Reference><Reference><Citation>Okkersen &#xa0;K, Jimenez-Moreno &#xa0;C, Wenninger &#xa0;S, et al. &#xa0;Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol &#xa0;2018; 17:671&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">29934199</ArticleId></ArticleIdList></Reference><Reference><Citation>Raijmakers &#xa0;RPH, Keijmel &#xa0;SP, Breukers &#xa0;EMC, et al. &#xa0;Long-term effect of cognitive behavioural therapy and doxycycline treatment for patients with Q fever fatigue syndrome: one-year follow-up of the Qure study. J Psychosom Res &#xa0;2019; 116:62&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30654996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielissen &#xa0;MFM, Verhagen &#xa0;CAHHVM, Bleijenberg &#xa0;G. Cognitive behaviour therapy for fatigued cancer survivors: long-term follow-up. Br J Cancer &#xa0;2007; 97:612&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2360364</ArticleId><ArticleId IdType="pubmed">17653075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuut &#xa0;TA, M&#xfc;ller &#xa0;F, Aldenkamp &#xa0;A, et al. &#xa0;A randomised controlled trial testing the efficacy of Fit After COVID, a cognitive behavioural therapy targeting severe post-infectious fatigue following COVID-19 (ReCOVer): study protocol. Trials &#xa0;2021; 22:867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8637041</ArticleId><ArticleId IdType="pubmed">34857010</ArticleId></ArticleIdList></Reference><Reference><Citation>Worm-Smeitink &#xa0;M, Gielissen &#xa0;M, Bloot &#xa0;L, et al. &#xa0;The assessment of fatigue: psychometric qualities and norms for the Checklist Individual Strength. J Psychosomatic Res &#xa0;2017; 98:40&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28554371</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaronson &#xa0;NK, Muller &#xa0;M, Cohen &#xa0;PDA, et al. &#xa0;Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol &#xa0;1998; 51:1055&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundt &#xa0;JC, Marks &#xa0;IM, Shear &#xa0;MK, Greist &#xa0;JH. The work and social adjustment scale: a simple measure of impairment in functioning. Br J Psychiatry &#xa0;2002; 180:461&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11983645</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins &#xa0;CA, Weathers &#xa0;FW, Davis &#xa0;MT, Witte &#xa0;TK, Domino &#xa0;JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress &#xa0;2015; 28:489&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">26606250</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck &#xa0;AT, Guth &#xa0;D, Steer &#xa0;RA, Ball &#xa0;R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for primary care. Behav Res Ther &#xa0;1997; 35:785&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan &#xa0;DV, Lecrubier &#xa0;Y, Sheehan &#xa0;KH, et al. &#xa0;The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry &#xa0;1998; 59(Suppl 20):22&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Castor. &#xa0;Castor electronic data capture system. Amsterdam, the Netherlands: Castor; 2019.</Citation></Reference><Reference><Citation>Bestall &#xa0;JC, Paul &#xa0;EA, Garrod &#xa0;R, Garnham &#xa0;R, Jones &#xa0;PW, Wedzicha &#xa0;JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax &#xa0;1999; 54:581&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1745516</ArticleId><ArticleId IdType="pubmed">10377201</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson &#xa0;NS, Truax &#xa0;P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol &#xa0;1991; 59:12&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke &#xa0;K, Spitzer &#xa0;RL, Williams &#xa0;JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med &#xa0;2002; 64:258&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11914441</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoop &#xa0;H, Van Der Meer &#xa0;JWM, Bleijenberg &#xa0;G. Guided self-instructions for people with chronic fatigue syndrome: randomised controlled trial. Br J Psychiatry &#xa0;2008; 193:340&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">18827302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen &#xa0;J. A power primer. Psychol Bull &#xa0;1992; 112:155&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19565683</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute for Statistics, United Nations Educational, Scientific and Cultural Organization (UNESCO) . International standard classification of education. 2011. Montreal, Canada: UNESCO Institute for Statistics, 2012.</Citation></Reference><Reference><Citation>Morley &#xa0;S, Dowzer &#xa0;CN. Manual for the Leeds reliable change indicator: simple Excel applications for the analysis of individual patient and group data. Leeds, UK: University of Leeds, 2014.</Citation></Reference><Reference><Citation>Thewes &#xa0;B, Rietjens &#xa0;JAC, van den Berg &#xa0;SW, et al. &#xa0;One way or another: the opportunities and pitfalls of self-referral and consecutive sampling as recruitment strategies for psycho-oncology intervention trials. Psycho-Oncology &#xa0;2018; 27:2056&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6100450</ArticleId><ArticleId IdType="pubmed">29808508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimeno-Almaz&#xe1;n &#xa0;A, Franco-L&#xf3;pez &#xa0;F, Buend&#xed;a-Romero &#xa0;&#xc1;, et al. &#xa0;Rehabilitation for post-COVID-19 condition through a supervised exercise intervention: a randomized controlled trial. Scand J Med Sci Sports &#xa0;2022; 32:1791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538729</ArticleId><ArticleId IdType="pubmed">36111386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>